The company said net sales for Q3 2026 were $13,013 million, up 14.5% on a reported basis and 7.0% on a comparable basis. GAAP net earnings were $920 million, and GAAP diluted EPS was $0.53.

1. 01

   The company said net sales for Q3 2026 were $13,013 million, up 14.5% on a reported basis and 7.0% on a comparable basis. GAAP net earnings were $920 million, and GAAP diluted EPS was $0.53.

2. 02

   The company said net earnings excluding specified items for Q3 were $2,477 million ($2,278 million in the year-earlier quarter), and adjusted diluted EPS was $1.42 ($1.30 in the year-earlier quarter). It said specified items totaled $1,689 million before taxes.

3. 03

   The company cited specified items for Q3 2026 that included intangible amortization of $841 million, legal settlements of about $670 million, and other net expenses of $178 million tied to acquisitions, restructuring and other items. The legal settlements resolve the Gill case and NEC claims for about 2,000 infants.

4. 04

   The company said it expects 2026 comparable sales growth of about 6.0%, adjusted diluted EPS of $5.50 to $5.55, and adjusted diluted EPS for Q4 of $1.62 to $1.67. It kept the midpoint of its prior full-year EPS range and narrowed the range.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.